A longitudinal study across two major U.S. health databases found nucleoside reverse transcriptase inhibitors to be associated with reduced Alzheimer's disease incidence.
FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.